Teva Should Post Bond For Copaxone During Supreme Court Patent Review – Sandoz, Mylan Argue
This article was originally published in The Pink Sheet Daily
Executive Summary
Allowing an injunction against a Federal Circuit opinion would in essence decide the case in Teva’s favor, generic firms contend, since now-invalidated manufacturing patent is set to expire in September 2015 anyway.
You may also be interested in...
Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.